Selective toxin expression in angiogenic endothelial cells
AssigneeUniversity Technology Corporation
InventorsIan H. Maxwell, Francoise Maxwell, Cortina Kaletta, Kurt W. Naujoks
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions capable of specifically inducing cell death in the proliferating angiogenic endothelial cells associated with solid tumors and other angiogenesis associated diseases. More specifically, the present invention relates to nucleotide constructs that are selectively active in angiogenic endothelial cells and that encode highly toxic agents, such as diphtheria toxin, for expression in such cells.
Claims23
An isolated nucleic acid molecule comprising a sequence that encodes a highly toxic protein and regulatory elements effective to selectively express the sequence in angiogenic endothelial cells.
Dependencies are inferred from the claim text.